{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"A DLT was defined as:\n\n* Death not related to disease progression\n* Grade (Gr) 4 (Life-threatening) neurotoxicity\n* Gr 3 (Severe) neurotoxicity of greater than 7 days\n* Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event\n* Seizures of grade that do not resolve within 7 days\n* Gr 4 cytokine release syndrome (CRS) that does not resolve to less than or equal to Gr 3 within 3 days\n* Gr 3 CRS that does not resolve to less than or equal to Grade 2 within 7 days\n* Any increase in aspartate aminotransferase (AST) or ALT \\\\\\> 3 Ã- ULN and concurrent increase in total bilirubin \\\\\\> 2 Ã- ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases\n* Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee","groups":[{"description":"Participants with KRAS G12C-mutant Advanced Solid Tumors were treated with a single dose of BMS-986466 10 mg orally (PO) on Cycle 1 Day 1 and Day 9 and followed by regular administration from Cycle 3 Day 1 till study discontinuation. Participants were also administered with adagrasib 400 mg twice a day (BID) starting on Cycle 1 Day 4.","id":"OG000","title":"Part 1: Drug-Drug Interaction (DDI) - BMS986466 10 MG + Adagrasib 400MG BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants were considered DLT evaluable if they complete ≥ 75% of all planned doses of BMS-986466 and adagrasib without experiencing a DLT or experience a DLT after receiving at least 1 dose of BMS-986466 and adagrasib. Participants were not enrolled in Part 1a, 1b. Prespecified to be collected for Part 1 only","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Each cycle consist of 28 days)","title":"Part 1: Number of Participants With Dose Limiting Toxicity (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}